Abbisko Cayman (HKG:2256) unit Abbisko Therapeutics said that the first gastric cancer patient had been dosed in its phase II clinical study to evaluate ABSK061 and ABSK043 for solid tumors.
A Phase II clinical trial is underway to evaluate the safety and effectiveness of ABSK061 and ABSK043 with or without chemotherapy in patients with metastatic or unresectable advanced solid tumors with FGFR2/3 alterations, according to a Friday disclosure with the Hong Kong Exchange.
ABSK061 is a clinically advanced, orally bioavailable, potent, and selective inhibitor of FGFR2 and FGFR3, while ABSK043 is an orally available, potent inhibitor targeting PD-L1.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。